Zoledronic Acid Markedly Improves Bone Mineral Density for Patients with Monoclonal Gammopathy of Undetermined Significance and Bone LossJames R. Berenson, Regina A. Swift, Ori Yellin et al.|Clinical Cancer Research|2008Cited by 70
Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL)James R. Berenson, R. Swift, Stephen Heung‐Sang Wong et al.|Journal of Clinical Oncology|2008Cited by 2